Showing results (221-230 of 325) with videos related to
Sort By:
Pageof 33
Journal of Medicinal Chemistry|August 17, 2013
Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studiesArun K Ghosh, Garth L Parham, Cuthbert D Martyr, et al.The International Journal of Biochemistry & Cell Biology|May 20, 2008
2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variantsAtsushi Kawamoto, Eiichi Kodama, Stefan G Sarafianos, et al.Journal of Medicinal Chemistry|October 26, 2018
Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural StudiesArun K Ghosh, Jacqueline N Williams, Rachel Y Ho, et al.Antimicrobial Agents and Chemotherapy|June 6, 2007
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosineHirotomo Nakata, Masayuki Amano, Yasuhiro Koh, et al.Journal of Virology|January 5, 2002
A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active siteKazuhisa Yoshimura, Ryohei Kato, Mark F Kavlick, et al.Antiviral Research|April 11, 2017
Early phase dynamics of traceable mCherry fluorescent protein-carrying HIV-1 infection in human peripheral blood mononuclear cells-transplanted NOD/SCID/Jak3-/- miceNobuyo Higashi-Kuwata, Hiromi Ogata-Aoki, Shin-Ichiro Hattori, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|May 8, 2021
Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodiesMakoto Inada, Masahiro Ishikane, Mari Terada, et al.Journal of Virology|November 20, 2015
C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including DarunavirManabu Aoki, Hironori Hayashi, Ravikiran S Yedidi, et al.Bioorganic & Medicinal Chemistry|June 15, 2010
Discovery of orally available spirodiketopiperazine-based CCR5 antagonistsRena Nishizawa, Toshihiko Nishiyama, Katsuya Hisaichi, et al.Scientific Reports|July 2, 2020
Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticityHaydar Bulut, Shin-Ichiro Hattori, Hiromi Aoki-Ogata, et al.Pageof 33